ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0281

Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0121

Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0207

Investigation of Delays in Cancer Screening in RA

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0311

Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30AM: Abstract Number: PP04

Involving Pediatric Patients in Their Own Care

Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0550

Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0504

Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0380

Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0287

Joint Involvement in Cystic Fibrosis: Description of Clinical Phenotypes

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0685

KL-6 and IL-18 Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Enhancing Prognostic Insights into Early Detection, Progression, Lung Volume Changes,and Mortality Risk

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0157

Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0450

Knowledge, Attitudes, and Intention Towards HPV Vaccination Among Reproductive-Age Women with Rheumatic Diseases

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0576

Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0166

Limitations in Activities of Daily Living Among Individuals with SLE

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0709

Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records

Systemic Sclerosis & Related Disorders – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].